488 related articles for article (PubMed ID: 30700254)
21. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.
Engert F; Kovac M; Baumhoer D; Nathrath M; Fulda S
Oncotarget; 2017 Jul; 8(30):48794-48806. PubMed ID: 27447864
[TBL] [Abstract][Full Text] [Related]
22. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1659-1670. PubMed ID: 32279088
[TBL] [Abstract][Full Text] [Related]
23. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
24. Inhibiting the MCM8-9 complex selectively sensitizes cancer cells to cisplatin and olaparib.
Morii I; Iwabuchi Y; Mori S; Suekuni M; Natsume T; Yoshida K; Sugimoto N; Kanemaki MT; Fujita M
Cancer Sci; 2019 Mar; 110(3):1044-1053. PubMed ID: 30648820
[TBL] [Abstract][Full Text] [Related]
25. Poly ADP Ribose Polymerase Inhibitor Olaparib Targeting Microhomology End Joining in Retinoblastoma Protein Defective Cancer: Analysis of the Retinoblastoma Cell-Killing Effects by Olaparib after Inducing Double-Strand Breaks.
Jiang Y; Yam JC; Chu WK
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639028
[TBL] [Abstract][Full Text] [Related]
26. Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma.
Karatkevich D; Deng H; Gao Y; Flint E; Peng RW; Schmid RA; Dorn P; Marti TM
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233258
[TBL] [Abstract][Full Text] [Related]
27. Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway.
Sinha S; Chatterjee S; Paul S; Das B; Dash SR; Das C; Kundu CN
Exp Cell Res; 2022 Nov; 420(1):113338. PubMed ID: 36075449
[TBL] [Abstract][Full Text] [Related]
28. MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.
Yi J; Liu C; Tao Z; Wang M; Jia Y; Sang X; Shen L; Xue Y; Jiang K; Luo F; Liu P; Cheng H
EBioMedicine; 2019 May; 43():225-237. PubMed ID: 30898650
[TBL] [Abstract][Full Text] [Related]
29. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
[TBL] [Abstract][Full Text] [Related]
30. Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.
Mairinger FD; Vollbrecht C; Flom E; Christoph DC; Schmid KW; Kollmeier J; Popper HH; Mairinger T; Walter RFH
Oncotarget; 2017 Jun; 8(23):37502-37510. PubMed ID: 28415584
[TBL] [Abstract][Full Text] [Related]
31. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
32. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
[TBL] [Abstract][Full Text] [Related]
33. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.
Daemen A; Wolf DM; Korkola JE; Griffith OL; Frankum JR; Brough R; Jakkula LR; Wang NJ; Natrajan R; Reis-Filho JS; Lord CJ; Ashworth A; Spellman PT; Gray JW; van't Veer LJ
Breast Cancer Res Treat; 2012 Sep; 135(2):505-17. PubMed ID: 22875744
[TBL] [Abstract][Full Text] [Related]
34. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
Cheng H; Zhang Z; Borczuk A; Powell CA; Balajee AS; Lieberman HB; Halmos B
Carcinogenesis; 2013 Apr; 34(4):739-49. PubMed ID: 23275151
[TBL] [Abstract][Full Text] [Related]
35. Olaparib.
Bochum S; Berger S; Martens UM
Recent Results Cancer Res; 2018; 211():217-233. PubMed ID: 30069770
[TBL] [Abstract][Full Text] [Related]
36. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.
Cioce M; Ganci F; Canu V; Sacconi A; Mori F; Canino C; Korita E; Casini B; Alessandrini G; Cambria A; Carosi MA; Blandino R; Panebianco V; Facciolo F; Visca P; Volinia S; Muti P; Strano S; Croce CM; Pass HI; Blandino G
Oncogene; 2014 Nov; 33(46):5319-31. PubMed ID: 24240684
[TBL] [Abstract][Full Text] [Related]
37. Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
Monica V; Lo Iacono M; Bracco E; Busso S; Di Blasio L; Primo L; Peracino B; Papotti M; Scagliotti G
Oncotarget; 2016 Nov; 7(47):76577-76589. PubMed ID: 27391433
[TBL] [Abstract][Full Text] [Related]
38. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B
J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272
[TBL] [Abstract][Full Text] [Related]
39. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells.
Minami D; Takigawa N; Takeda H; Takata M; Ochi N; Ichihara E; Hisamoto A; Hotta K; Tanimoto M; Kiura K
Mol Cancer Res; 2013 Feb; 11(2):140-8. PubMed ID: 23239809
[TBL] [Abstract][Full Text] [Related]
40. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
